Kh., A., M., A., H., H. (2019). SUBCONJUCTIVAL INJECTION OF BEVACIZUMAB IN CORNEAL NEOVASCULARIZATION. Egyptian Journal of Clinical Ophthalmology, 2(2), 69-74. doi: 10.21608/ejco.2019.162986
Ali, Kh.; Abd El-badie, M.; Hassan, H.. "SUBCONJUCTIVAL INJECTION OF BEVACIZUMAB IN CORNEAL NEOVASCULARIZATION". Egyptian Journal of Clinical Ophthalmology, 2, 2, 2019, 69-74. doi: 10.21608/ejco.2019.162986
Kh., A., M., A., H., H. (2019). 'SUBCONJUCTIVAL INJECTION OF BEVACIZUMAB IN CORNEAL NEOVASCULARIZATION', Egyptian Journal of Clinical Ophthalmology, 2(2), pp. 69-74. doi: 10.21608/ejco.2019.162986
Kh., A., M., A., H., H. SUBCONJUCTIVAL INJECTION OF BEVACIZUMAB IN CORNEAL NEOVASCULARIZATION. Egyptian Journal of Clinical Ophthalmology, 2019; 2(2): 69-74. doi: 10.21608/ejco.2019.162986
SUBCONJUCTIVAL INJECTION OF BEVACIZUMAB IN CORNEAL NEOVASCULARIZATION
1Ophthalmology dept., Faculty of Medicine, AL-Azhar Univ., Assuit, Egypt
2Ophthalmology dept, Faculty of Medicine, AL-Azhar Univ. Cairo, Egypt
Abstract
Purpose: The aim of this work was to assess the outcome of subconjunctival bevacizumab (Avastin) injection in patients with corneal neovascularization (NV). Methods: Twenty eyes of twenty patients (13 male and 7 female) with corneal neovascularization resulted from variable ocular surface disorders were included in this prospective, non-controlled study. All eyes received a single subconjunctival injection of 2.5 mg (0.1 ml) bevacizumab using 1 ml syringe 27 Guage needle. Morphological changes in the major and minor vessels were studied by slitlamp biomicroscopy and corneal photography pre-injection and one week, 2 months and 6 months post injection. Results: Obvious recession of minor vessels of Corneal NV was noticed in most eyes at first week post-injection. The extent of corneal neovascularization of the major vessels was significantly decreased 1weeks post-injection. This decrease continued noticeably for 6 months. Conclusions: Bevacizumab can be safely and effectively used in corneal NV treatment. It can be considered in the treatment of both minor and major vessel NV resulted from long standing chronic inflammation (trachoma), long-standing corneal ischemia (following contact lens wear) and other different causes. Bevacizumab was well tolerated over the monitoring period in this research. Further controlled and long term studies are required to fully evaluate the long term effects of this recent treatment.